Abstract:Aims: Cardiovascular disease remains a major global health concern, with atherosclerosis (AS) being a significant contributor. Vulnerable plaques play a critical role in acute cardiovascular events. Syndecan-1 (SDC-1), a vital membrane proteoglycan in the vascular endothelial glycocalyx, is believed to be associated with plaque progression. However, its precise relationship with severity and vulnerability of atherosclerotic plaque remains unclear. This study aimed to investigate SDC-1 expression and its potential correlation with plaque vulnerability in ApoE-/- atherosclerosis mouse model. Methods and results: Eight-week-old mice were induced into the AS model using a high-fat diet (HFD) and/or partial ligation of the left common carotid artery (PLCA), with a chow diet (CD) control group. After 16 weeks, plaques in the aortic root showed the following order: HFD + PLCA group > HFD group > CD + PLCA group > CD group. Immunohistochemistry revealed heightened accumulation of lipid/foam cells and CD68-labeled macrophages in the plaques, elevated vascular endothelial growth factor (VEGF), and matrix Metalloproteinase-9 (MMP-9) in the HFD + PLCA group's plaques, along with reduced collagen and α-SMA-labeled smooth muscle cells, resulting in the highest vulnerability index value. Immunohistofluorescence analysis of frozen plaque sections showed significantly higher SDC-1 expression in the AS mice group compared to the CD group, both positively correlated with plaque vulnerability. Serum analysis demonstrated elevated levels of SDC1, sphingosine 1-phosphate (S1P), and VEGF-A in the AS mice, all positively correlated with plaque vulnerability. Multivariate analysis identified SDC1 as an independent predictor of plaque vulnerability. Conclusion: This study enhances our understanding of plaque vulnerability mechanisms and presents SDC1 as a potential biomarker for atherosclerosis. These findings underscore the importance of addressing modifiable risk factors, such as diet and hemodynamics and suggest the utility of serum SDC1 as a valuable clinical marker. Ultimately, these insights may lead to more effective strategies in combating cardiovascular diseases and improving patient outcomes.

Syndecan-1: A Novel Diagnostic and Therapeutic Target in Liver Diseases.

The Role and Therapeutic Value of Syndecan-1 in Cancer Metastasis and Drug Resistance

Syndecan-1 Serves As the Major Receptor for Attachment of Hepatitis C Virus to the Surfaces of Hepatocytes

Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy

Syndecan-1 as a predictor of vulnerable atherosclerotic plaques

Therapeutic Potential of Targeting Membrane-Spanning Proteoglycan SDC4 in Hepatocellular Carcinoma

Syndecan-4 promotes vascular beds formation in tissue engineered liver via thrombospondin 1

SDC1 promotes cisplatin resistance in hepatic carcinoma cells via PI3K-AKT pathway

The Key Protein Machineries in Regulating Liver De-velopment, Regeneration and Size Control

Syndecan-4 protects against osteopontin-mediated acute hepatic injury by masking functional domains of osteopontin.

Emerging Importance of Chemokine Receptor CXCR4 and Its Ligand in Liver Disease

Roles and therapeutic targeting of dendritic cells in liver fibrosis

Novel roles of DC-SIGNR in colon cancer cell adhesion, migration, invasion, and liver metastasis

The role of sirtuin1 in liver injury: molecular mechanisms and novel therapeutic target

Interorgan communication with the liver: novel mechanisms and therapeutic targets

Syndecans in hematopoietic cells and their niches

Liver Sinusoidal Endothelial Cell: An Important Yet Often Overlooked Player in the Liver Fibrosis

Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases

Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach

Functional Roles of Chemokine Receptor CCR2 and Its Ligands in Liver Disease

Critical Roles of the Sphingolipid Metabolic Pathway in Liver Regeneration, Hepatocellular Carcinoma Progression and Therapy